Diagnostic · In Clinical Trials
Bombesin Analog Tracers
No lawful US pathway
01 · Overview
Bombesin analogue tracers are synthetic peptides based on the amphibian peptide bombesin or its mammalian counterpart gastrin-releasing peptide, radiolabeled for molecular imaging. They bind gastrin-releasing peptide receptors, which are overexpressed in prostate and breast cancers among others, allowing tumor visualization by PET or SPECT.
Both agonist and antagonist analogues have been labeled with radionuclides including gallium-68, fluorine-18, technetium-99m and copper-64, with the field shifting toward receptor antagonists, which show favourable tumor uptake and retention as well as greater inherent safety (PMID 26631238).
02 · Research summary & key findings
In a first clinical evaluation of the antagonist gallium-68 SB3, PET/CT caused no adverse effects and showed pathological uptake in about half of 17 patients with advanced breast or prostate cancer (PMID 26631238). In 50 patients with biochemically recurrent prostate cancer, gallium-68 RM2 detected fewer lesions overall than PSMA-targeted tracers but found lesions that the PSMA scans missed in a small number of patients, suggesting a complementary rather than superior role (PMID 33674398). No bombesin analogue tracer has achieved FDA approval, and trials of gastrin-releasing peptide receptor agents, including therapeutic lutetium-177 labeled analogues, are currently recruiting or active on ClinicalTrials.gov.
03 · Regulatory status
Bombesin Analog Tracers is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
No lawful pathway today
Bombesin Analog Tracers is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding.
See the 2 FDA-approved compounds in Diagnostic
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
04 · Administration routes
- Intravenous
References
- [1]Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT Eur J Nucl Med Mol Imaging, 2016. PMID 26631238
- [2]PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer J Nucl Med, 2021. PMID 33674398
Primary literature
- PubMed: "Bombesin Analog Tracers"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Bombesin Analog Tracers"
Registered interventional and observational studies, including status and phase.
- PubChem: "Bombesin Analog Tracers"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Diagnostic
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.